Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 14/20 | 0.50 |
| ▸ | THRA | P10827 | 13/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929691 | 0.90 | THRA (0.52) | THRBTHRADHODHESR1NR3C1 | |
| SCHEMBL4934191 | 0.85 | EGLN1 (0.36) | THRBTHRADHODHPTPN1MRGPRX4 | |
| SCHEMBL5718319 | 0.85 | THRB (0.51) | THRBTHRADHODHPTPN1ESR1 | |
| SCHEMBL4932002 | 0.84 | THRB (0.50) | THRBTHRADHODHPTPN1ESR1 | |
| SCHEMBL4932765 | 0.84 | THRB (0.50) | THRBTHRADHODHPTPN1 | |
| SCHEMBL4931340 | 0.83 | THRB (0.51) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4927550 | 0.82 | THRB (0.53) | THRBTHRADHODHPTPN1ESR1 | |
| SCHEMBL4932606 | 0.82 | THRB (0.49) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5717898 | 0.82 | MRGPRX4 (0.35) | THRBTHRAMRGPRX4PTGDR2 | |
| SCHEMBL4934533 | 0.82 | THRB (0.47) | THRBTHRAPTPN1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | KARO BIO AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1732533-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092317-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885DHODH 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.